The mechanism of action of asenapine is not fully understood. However, based on its receptor pharmacology, it is proposed that the efficacy of asenapine is mediated through a combination of antagonist activity at D2 and 5-HT2A receptors. Actions at other receptors e.g. 5-HT1A, 5-HT1B, 5-HT2C, 5-HT6, 5-HT7, D3, and a2-adrenergic receptors, may also contribute to the clinical effects of asenapine.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Asenapine is the active ingredient of these drugs:
Australia Canada New Zealand United States
Austria Cyprus Finland Ireland Lithuania
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):